Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03544060
Expanded Access Status : No longer available
First Posted : June 1, 2018
Last Update Posted : September 16, 2021
CaligorRx, Inc.
Information provided by (Responsible Party):
Akcea Therapeutics

Brief Summary:
The purpose of this program is to provide expanded access to volanesorsen for up to 100 Patients with Familial Chylomicronemia Syndrome (FCS).

Condition or disease Intervention/treatment
Familial Chylomicronemia Drug: Volanesorsen

Detailed Description:
The Program is intended to provide expanded access to volanesorsen for eligible patients with FCS who have limited or no available treatment options.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
Official Title: Volanesorsen (ISIS 304801) Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Intervention Details:
  • Drug: Volanesorsen
    Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
    Other Name: Waylivra

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients who participated in the APPROACH Open Label trial, must have completed the open label extension trial for volanesorsen for a length of time consistent with the study protocol (≥ 1 year). Patients in the APPROACH open Label trial for less than a year require approval from Akcea to participate in the EAP. Patients who did not participate in the APPROACH open label trial require approval from Akcea for entry into EAP.
  • Patients not participating in the APPROACH open label trial must have a diagnosis of FCS as determined by the participating physician, as outlined in the Volanesorsen EAP protocol. Akcea will review each application to determine eligibility.
  • Male patients and female patients of childbearing potential must continue to use appropriate contraception with their partners, or refrain from sexual activity

Exclusion Criteria:

  • Patients who have any new conditions or worsening of existing conditions which in the opinion of the Physician would make the patient unsuitable for treatment with volanesorsen.
  • Volanesorsen naïve patients with baseline platelet values ≤ 140,000/mm3
  • Patients not willing to adhere to mandatory blood draws for platelet monitoring
  • Patients who in the opinion of Akcea's medical team, are not eligible candidates for volanesorsen therapy.
  • Any patient who plans to or becomes pregnant.
  • Any patient who was withdrawn from the APPROACH open label study due to a serious adverse event related to volanesorsen therapy.

No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: Akcea Therapeutics Identifier: NCT03544060    
Other Study ID Numbers: ISIS 304801
First Posted: June 1, 2018    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021
Keywords provided by Akcea Therapeutics:
Familial Chylomicronemia
Familial Lipoprotein Lipase Deficiency
Familial Hyperlipoproteinemia Type 1
Hyperlipoproteinemia Type 1
Hyperchylomicronemia, Familial
Lipoprotein Lipase Deficiency, Familial
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Metabolic Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperlipoproteinemia Type I
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism Disorders
Metabolic Diseases